Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2022 Financial Results

Elwanda Tulloch

Quoin Pharmaceuticals, Inc. Initiates clinical trial evaluating lead product candidate, QRX003 for Netherton SyndromeExpands number of commercial partnerships to eight, covering 60 countriesSigns Research Agreement to develop a product for the treatment of scleroderma Closes $16.8 million public offering, with net proceeds of approximately $15.0 million ASHBURN, Va., Aug. 18, […]

Subscribe US Now